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Abstract: Inclusion body myositis is a rare, late-onset 
myopathy. Both inflammatory and myodegenerative 
features play an important role in their pathogenesis. 
Overlapping clinicopathological entities are the famil-
ial inclusion body myopathies with or without demen-
tia. These myopathies share several clinical and patho-
logical features with the sporadic inflammatory disease. 
Therefore, better understanding of the genetic basis and 
pathomechanism of these rare familial cases may advance 
our knowledge and enable more effective treatment 
options in sporadic IBM, which is currently considered a 
relentlessly progressive incurable disease. 
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1  Introduction
Inclusion body myositis (IBM), as well as polymyositis, 
and dermatomyositis are inflammatory myopathies [1]. 
Sporadic (sIBM) is a late-onset myopathy, representing the 
most common muscle disease above the age of 50 years 
[2]. The clinical phenotype of the disease is well-defined, 
both inflammatory and myodegenerative features can be 
highlighted during their pathogenesis [1]. However, IBM 
is a slowly progressive disease with no effective treat-
ment [3]. In inclusion body myositis the typical features 
are muscle weakness and atrophy in the quadriceps 
femoris muscle and in the flexors of the wrist and fingers. 
The most frequent concomitant signs are dysphagia and 
asymmetric weakness. The serum creatine kinase level is 
usually under 2000 U/L [4]. The prevalence of the disease 
is 3.5/100.000, but it moves on a range scale, and varies 
among different countries, and ethnic groups [5]. This 
intense diversity may be caused by the combination of dif-
ferent genetic, and environmental factors of the affected 
racial groups [6]. This disease is most common in males, 
the male:female ratio is 3:1. The characteristic clinical 
features of IBM display some overlap with hereditary 
frontotemporal dementia, FTLDs: frontotemporal lobar 
degenerations, GNE: UDP-N-acetylglucosamine-2-
epimerase/N-acetylmannosomine kinase; hIBM: hered-
itary inclusion body myopathy; HLA: human leukocyte 
antigen; IBM: inclusion body myositis; IBMPFD: IBM with 
early-onset Paget disease and frontotemporal dementia; 
iNOS: inducible NO synthase, LC3:   1A/1B-light chain 3, 
MHC: major histocompatibility complex; MRI: magnetic 
resonance imaging; MYHC2A: myosin heavy chain IIa; 
PCR: polymerase chain reaction; PM: polymyositis; sIBM: 
sporadic inclusion body myositis; SIRT1: NAD-dependent 
deacetylase sirtuin-1; TDP-43: TAR DNA-binding protein 
43; TGFβ1: transforming growth factor beta 1; VCP: 
valosin-containing protein;  ZASP: Z-band alternatively 
spliced PDZ-motif protein
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inclusion body myopathy (hIBM) which makes the diag-
nosis of sIBM more difficult. However the genetic charac-
teristics of sIBM and hIBM are different [1]. In this review, 
we briefly introduce the genetic susceptibility factors for 
sIBM as well as the typical genetic background of hIBM. 
Furthermore, we describe the main processes associated 
with the pathogenesis of this disorder. Finally, we intro-
duce the inclusion body myopathy with early-onset Paget 
disease and frontotemporal dementia, which is a special 
subtype of IBM.
2  Genetic background of IBM
Inclusion body myopathies can be classified as familial 
or hereditary inclusion body myopathies (hIBM) or spo-
radic inclusion body myositis (sIBM) [2]. Hereditary and 
sporadic IBM share several common pathological fea-
tures, including rimmed vacuoles, intracytoplasmic, and 
intranuclear tubulofilamentous inclusions. In spite of 
sporadic IBM, the muscle biopsies from a patient affected 
with the hereditary form of IBM, do not show inflamma-
tion. This phenomenon explains the ’myopathy’ nomi-
nation. Moreover, hIBM can be further characterised by 
the earlier age of onset and negative MHCI staining of the 
muscle biopsy. On the other hand, the role of both inflam-
matory and degenerative processes are important in the 
pathogenesis of sIBM [7]. In addition to this, there are also 
differences in the genetic background in these two types 
of IBM. Moreover, the clinical features of sIBM display 
some overlap with hereditary inclusion body myopathies 
[8]. In the next section of our review, we briefly highlight 
the main genetic differences between sporadic and hered-
itary IBM. 
2.1  Genetic susceptibility factors for sIBM
As we mentioned in the introduction, multiple genetic 
factors may play an important role during the develop-
ment and the pathogenesis of sporadic IBM [6]. Similar 
to other autoimmune diseases, in Caucasians the sIBM 
is associated with the HLA-DR3 allele and the 8.1 ances-
tral MHC haplotype: HLA-A*01:01, HLA-B*08:01, HLA-
DRB1*03:01, HLA-DRB3*01:01 and HLA-DQA1*05:01 [9]. 
Moreover, the HLA-DRB1*03:01 and HLA-DRB1*13:01 
alleles may have an influence on the onset of the disease, 
and severity of muscle weakness [10]. Koffman and col-
leagues described that sIBM is a distinct disorder with a 
strong immunogenetic background. They analysed the 
HLA class II associations in patients with sIBM, and hIBM. 
The frequency of HLA-DRB1*03:01, HLA-DRB3*01:01 or 
HLA-DRB3*02:02, as well as HLA-DQB1*02:01 alleles were 
more than 77% in sIBM, but they did not find a signifi-
cant association with these alleles in the DR and DQ hap-
lotypes among the 15 hIBM patients [7]. In a recent study, 
Rojana-Udomsart et al. analysed the HLA-DRB3 alleles 
and typical MHCII genotypes in sIBM. They found asso-
ciations with the carriage of the DRB3*01:01 allele which 
was accounted for by its linkage disequilibrium with the 
DRB1*03:01 allele. Moreover, the carriage of the HLA-DRB4 
allele was found to be protective, in addition it dissolved 
the risk effect of HLA-DRB1*03:01. Their results indicate 
that haplotypic combinations of alleles at the HLA-DRB1 
and secondary HLA-DRB loci have an important risk mod-
ifying effect in sIBM [10]. Cai et al. analysed the three fre-
quent mutated genes of hIBM (DES, GNE, and MYHC2A), 
as well as two additional genes (VCP, and ZASP) in 21 sIBM 
patients. They did not find any missense mutations in the 
DES, VCP or GNE genes. On the other hand, three patients 
carried a missense mutation c.2542T>C (p.V805A) in the 
MYHC2A gene, and another patient carried a missense 
mutation c.1719G>A (p.V566M) in the ZASP gene [8]. 
2.2  Genetics of hereditary IBM
Hereditary IBM is a heterogeneous group of adult-onset 
muscle disorders with autosomal-dominant (AD) or auto-
somal-recessive (AR) pattern of inheritance (Figure 1.). 
According to the affected genes hIBM can be divided into 
three different types: IBM1, IBM2, and IBM3 [8]. Mutations 
in the DES (Desmin, 2q35) gene can lead to IBM1, other-
wise known as desmin related myopathy. The majority of 
known mutations of the DES gene show an autosomal dom-
inant inheritance pattern, but some of these alterations 
are autosomal recessive [6]. The characteristic genetic 
alteration of the second type of hereditary IBM (IBM2) 
is the mutated GNE gene (UDP-N-acetylglucosamine-2-
epimerase/N-acetylmannosomine kinase). This gene is 
localised on chromosome 9p13.3, and its mutations are 
autosomal recessive [8]. At present, we know more than 
50 mutations of the GNE gene that are associated with 
hIBM have been described worldwide [11]. Fischer et al. 
analysed for mRNA-expression markers of cellular stress, 
inflammation and β-amyloid of IBM2 patients and com-
pared to non-myopathic controls. The cellular stress 
molecules αB-crystallin and iNOS are overexpressed in 
IBM2 muscle and may identify early disease mechanisms. 
This result helps us to better understand the patholog-
ical processes of IBM2 [12]. Sequence analysis of GNE 
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revealed IBM2 individuals were compound heterozy-
gous for a mutation in the 5’ splice donor site of intron 
10 (c.1816+5G>A), and a missense mutation (c.2086G>A, 
p.V696M), confirming the diagnosis as IBM2. The splice 
site mutation correlated with the exclusion of exon 10 
from the transcript, which is predicted to produce an 
in-frame deletion (p. G545_D605del) of 61 amino acids in 
the kinase domain of the GNE protein [13]. The third type 
of IBM (IBM3) follows a pattern of AD inheritance. IBM3 
results from mutations in the MYHC2A gene, located on 
chromosome 17p13.1, and it encodes the myosin heavy 
chain IIa [8].
3  Pathogenesis of IBM
The pathomechanism of IBM is a complex process, includ-
ing many factors. Both the degeneration of the muscle 
fibres and the presence of mononuclear cells are an 
important during the pathogenesis; however their rela-
tionship is still unknown. Ascanas et al. summarise the 
typical cellular abnormalities of the disease in their review, 
and they emphasised that degeneration is the key factor 
in the muscle weakness. Several proteins can be accu-
mulated as inclusions in the cytoplasm of muscle fibres: 
amyloid-β42, and its different oligomers, as well as phos-
phorylated tau protein in double helical filaments. These 
proteins probably cause the degeneration of the fibres in 
IBM. In addition, there are other proteins that could play a 
part in the muscle fibre destruction: prion protein, ubiqui-
tin, cathepsin B and D, α1-antichimotripsin, ApoE, BACE1, 
BACE2, TGFβ1, cystatin C, superoxide-dismutase, many 
interleukins, transglutaminase 1 and 2, and γ-tubulin [14]. 
The suspected factors also include the stress upon rough 
endoplasmic reticulum and the reduced deacetylase activ-
ity of SIRT1. According to Askanas, all these phenomena 
are provoked by the aging of the intracellular milieu [15]. 
Weihl et al. described three additional aggregates: TDP-43, 
p62, and LC3. Among these proteins TDP-43 differentiates 
IBM from other inflammatory myopathies [16]. In addi-
tion, TDP-43 are often associated with optineurin, which 
are also involved in the pathogenesis of IBM; moreover, 
optineurin-containing inclusions are observed in neuro-
degenerative diseases e.g. ALS and FTLD-TDP [17, 18]. 
The role of the T-cells have been known since the 
1980s, and activity of the B-cells have also been described 
in the affected muscle biopsy [14]. In IBM, the typical 
non-necrotic fibres are focally surrounded and invaded by 
CD8+ T-cells and macrophages. Ivanidze et al. classified 
the muscle fibres of five IBM patients according to muscle 
fibre invasion by immune cells. Moreover, they isolated 
the intracellular content of the fibres by laser associated 
microdissection, then analysed the samples by microarray 
hybridization and quantitative PCR. They observed HLA 
upregulation in both invaded and non-invaded fibres, 
opposite to the controls. Moreover, each chain of the 
interferon-gamma receptor and other interferon-gamma 
induced genes were also upregulated [19]. These obser-
vations indicate that the increased expression of HLA-1 is 
not enough for the CD8+ T-cells invading. Salajegheh et 
al. identified a 43 kDa muscle protein in IBM patients; this 
protein had never been detected in any other diseases or 
controls before. Therefore this protein can become a new 
biomarker in the future [20]. These results suggest exam-
ining of the humoral immunity will be the key to under-
stand the exact pathomechanism of disease.
4  Prognosis
As we mentioned, IBM is a slowly progressing disease, 
and unfortunately there is no effective therapy [3]. Only a 
Figure 1. The genetic features of the three types of hereditary 
inclusion body myopathy (IBM) and the IBM with early-onset Paget 
disease and frontotemporal dementia (IBMPFD). There are 4 types 
of familial IBM. Types 1, 3 and IBMPFD are autosomal dominant 
whereas IBM2 is autosomal recessive disease (for details see Dis-
cussion). IBM: Inclusion-body myopathy, DES: Desmin, GNE: UDP-
N-acetylglucosamine-2-epimerase/N-acetylmannosomine kinase, 
IBMPFD: IBM with early-onset Paget disease and frontotemporal 
dementia, MYHC2A: myosin heavy chain IIa, VCP: valosin-containing 
protein.
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subset of patients should respond to steroids temporarily, 
while others not. In the most cases, using Methotrexate, 
Cyclosporine A, Azathioprine, or Mycophenolate mofetil 
therapy are also ineffective [21, 22]. Nevertheless, this 
agent would be effective only in a subset of the patients, 
altogether these results are also disappointing. These 
data emphasise that degenerative process would be more 
important, than inflammation. Agents stimulating auto-
phagy, under development by cancer and neurodegenera-
tive disease researchers, would be possible candidates for 
clinical studies in IBM as well [23]. Barca and colleagues 
collected muscle samples of IBM, PM patients, and con-
trols. They found ANT1 reduction, and NF-κB overexpres-
sion in IBM muscle samples, that could explain the lack of 
apoptosis [24]. A study was carried out with a humanized 
monoclonal antibody, called alemtuzumab, and though 
the number of T-cells were decreased in the repeated 
muscle biopsy, resounding success was not achieved [25, 
26]. An Italian study tried to use simvastatin in the therapy 
of IBM, however it was not successful [27]. Physiotherapy, 
as in idiopathic inflammatory myopathies, may deceler-
ate the progression of IBM, and improve the quality of 
life. A key part of this disease is aiding the movements of 
the patients by wheelchairs and other medical aids that 
usually become necessary in 5-10 years from the onset 
[21, 28]. Cox et al. have followed 64 patients for 12 years, 
and they recognise the importance of long-term clinical 
follow-up in IBM. Forty-six patients died during the fol-
low-up period, while the others became seriously dis-
abled. In their cases, the lower limbs proved to be weaker, 
and 47% of the patients had to use a wheelchair. The most 
frequent cause of death was respiratory disease [29].
5  Inclusion body myopathy with 
early-onset Paget disease and fron-
totemporal dementia (IBMPFD) – a 
special subtype of IBM
In addition to the three types of hIBM, inclusion body 
myopathy with early-onset Paget disease and frontotem-
poral dementia (IBMPFD) is another form of the overlap-
ping diseases. The characteristic triad is the following: 
1. proximal and distal myopathy, with the morphology 
of IBM, appearing in the third or fourth decades of life, 
2. early onset Paget’s disease of the bone and 3. fron-
totemporal dementia. This rare autosomal dominant 
disorder is caused by missense mutations in the VCP 
(valosin-containing protein) gene, localised chromosome 
9p13.3 [30]. The presence of the VCP is not specific for 
IBMPFD, though. Normally, the VCP protein can be found 
intramyonuclearly, perinuclearly or in the sarcoplasm, 
but in case of IBMPFD the VCP forms sarcoplasmic and 
myonuclear inclusions [31]. 
Muscle weakness appears only in 30% of the patients. 
Therefore, it is important to investigate the familial occur-
rence of dementia, or Paget’s disease [32, 33]. The pro-
found tendon reflexes are often missing. As the disease 
progresses, patients have to use wheelchairs. The elevated 
CK level, electromyography, and muscle MRI may help 
achieve the correct diagnosis. In a subset of the cases, the 
histological features are similar as in IBM. If the typical 
basophil-rimmed vacuoles are not present in the major-
ity of patients; they are simply described as non-specific 
myopathies [34]. On the other hand, varying sizes of the 
fibres and accumulation of the endomysial connective 
tissue can be observed. If these signs are present, the vac-
uoles are localised in subsarcolemmally, as well as in the 
sarcoplasm. They have an irregular shape and contain 
basophil debris. Futhermore, eosinophil bodies were 
described in the muscles of some patients. Frontotemporal 
dementias (FTDs) are a subsection of neurodegenerative 
diseases that are characterised by the degeneration of the 
prefrontal and anterior temporal lobes; therefore should 
be called frontotemporal lobar degenerations (FTLDs). 
Approximately half of the patients have a familial occur-
rence of dementia that suggests a strong genetic back-
ground of the disease. A large group of FTLDs belongs to 
the class of FTLD-TDPs [35]. Inclusion bodies are positive 
for ubiquitin and TDP-43 are localised in the nuclei and 
cytoplasm of the affected neurons, and they are typical 
in FTLD-TDP and suggest a key part in their pathogenesis 
[36]. 
6  Conclusions
IBM is a slowly progrediating disease, and unfortunately 
there is still no effective therapy. The precise pathogene-
sis of inclusion body myositis remains unknown. In the 
majority of cases it is diagnosed only a few years after the 
appearance of the first symptoms. The muscle biopsy typ-
ically shows endomysial inflammation in sIBM, with inva-
sion of mononuclear cells into the non-necrotic fibers, 
as well as rimmed-vacuoles. It appears that both inflam-
mation and degeneration are present at the onset of the 
disease. The delay of the diagnosis and often inadequate 
therapy contributes that the disease leads to disability 
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in most of the cases. Furthermore, the importance of the 
genetic factors could be emphasised during the devel-
opment and the pathogenesis of IBM. In this review we 
summarised the main features of this relatively rare, but 
important entity.
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